APA (7th ed.) Citation

M, R., JP, S., CJ, W., BA, H., S, B., SK, A., . . . KD, M. (2022). Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(15), 3235. https://doi.org/10.1158/1078-0432.CCR-21-3078

Chicago Style (17th ed.) Citation

M, Radovich, et al. "Initial Phase I Safety Study of Gedatolisib Plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 28, no. 15 (2022): 3235. https://doi.org/10.1158/1078-0432.CCR-21-3078.

MLA (9th ed.) Citation

M, Radovich, et al. "Initial Phase I Safety Study of Gedatolisib Plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 28, no. 15, 2022, p. 3235, https://doi.org/10.1158/1078-0432.CCR-21-3078.